The global Immune Repertoire Sequencing Market was valued at USD 369.93 million in 2025 and is projected to reach USD 1,029.75 million by 2035, expanding at a CAGR of 10.78% during the forecast period 2026–2035. As per the SNS Insider report titled, “Immune Repertoire Sequencing Market Size, Share & Segmentation Analysis, by Technology, Application, Sequencing Type, End User, & Region | Global Forecast 2026–2035,” the market is witnessing accelerated adoption driven by precision medicine, oncology research, and immunotherapy advancements.

Rising Adoption of Immunotherapy and Precision Medicine Driving Market Expansion

Growing interest in immunotherapeutics has designed a growing demand for immune repertoire sequencing technologies. Immune repertoire sequencing technology offers a more granular profiling of the immune cells, allowing for things like biomarker identification and treatment efficacy monitoring. For instance, individual response to treatments, including anti-PD-1/PD-L1 drugs, has been investigated in clinical trials using immune repertoire sequencing.

The NGS technology remains the medium of choice due to the scalable and high-throughput property of the technology. Still single cell sequencing is attracting more and more attention as it can profile immune system at the single cell level through high-resolution. Needless to say, high costs associated with cutting-edge sequencing technologies are still there.

Key Report Highlights

  • By technology, Next-Generation Sequencing (NGS) dominated the market with a 54.72% share in 2025, while Single-Cell Sequencing is projected to grow at the fastest CAGR of 13.97% through 2035.

  • By application, cancer research accounted for the largest share of 46.81% in 2025, whereas vaccine development is expected to expand at the highest CAGR of 14.56%.

  • By sequencing type, T-Cell Receptor (TCR) sequencing led with a 58.30% share in 2025, while B-Cell Receptor (BCR) sequencing is forecast to grow at a CAGR of 13.34%.

  • By end user, pharmaceutical & biotechnology companies held a 41.56% share in 2025, while hospitals & clinics are anticipated to grow at a CAGR of 13.89%.

  • Regionally, North America dominated with a 42.78% market share in 2025, while Asia-Pacific is projected to grow at the fastest CAGR of 13.18%.

Regional Outlook

The largest contribution came from North America with a share of 42.78% accounting for the modern infrastructure of genomics, high investment on R&D, and large presence of biotechnology companies. Significant market growth in North America is mainly due to large-scale investments in genomics, rising investment in cancer research, and the development of genome sequencing technology for clinical practice.

  • U.S. Immune Repertoire Sequencing Market is expected to grow from USD 124.17 million in 2025 to USD 390.12 million by 2035, at a (CAGR) of 10.01%. The major Federal government spending on genomics and immunology research being led by NIH is propelling this market. Continuous integration of immune profiling for oncology applications and vaccines development in pipeline will scarce up lift the market development.

Asia-Pacific is expected to have the highest CAGR from 2026 to 2035 at 13.18%. Increase expenditure in biotechnology sector, in the emerging economies of China, India and Japan,will drive growth in this region. Furthermore, large scale initiatives in genomics in china and various initiatives in vaccine R&D and bio-therapeutics production in India are to gain a significant market share thus exhibiting lucrative growth in the market.

Recent Industry Developments

  • In 2025 Illumina broadened its existing immune profiling technologies with NGS technologies, providing high-throughput and accurate TCR and BCR measuring.

  • Thermo Fisher Scientific moved its Ion Torrent sequencing products closer to clinical applications with the ability to analyze clinical immune repertoires more quickly.

  • Adaptive Biotechnologies saw expansion of uses of the immunoSEQ technology platform, particularly in cancer and MRD detection.

  • Multi-omics capabilities, such as co-expression and immune receptor sequencing for immune profiling are developed by 10x Genomics using its technology suite.

Leading Companies in the Immune Repertoire Sequencing Market

  • Illumina

  • Thermo Fisher Scientific

  • Adaptive Biotechnologies

  • BGI Genomics

  • 10x Genomics

  • QIAGEN

  • F. Hoffmann-La Roche

  • Takara Bio

  • Oxford Nanopore Technologies

  • Agilent Technologies

  • Pacific Biosciences (PacBio)

  • Danaher Corporation

  • Azenta Life Sciences

  • Personalis

  • CD Genomics

  • iRepertoire

  • Creative Biolabs

  • Mission Bio

  • ENPICOM

  • Dolomite Bio